Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The ...

Novo Nordisk has shared positive results from a late-stage study of its investigational haemophilia A therapy Mim8 in ...

Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing ...

If we look back just 70 years, the prognosis for patients with haemophilia was remarkably different to what it is today. In fact, in the 1950s and 1960s, life expectancy for the disease was around ...

[iStockphoto] Haemophilia, a rare genetic blood disorder primarily affecting males, is a non-communicable disease (NCD) with global implications. According to the World Federation of Hemophilia ...

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated ...

Haemophilia is a blood disorder in which an ... Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection.

Hemophilia A patients with self-described problem joints were found to have worse clinical outcomes, with more pain, in a new study.

Hemlibra was found to ease pain and improve quality of life for hemophilia A patients, even those with long-term joint damage ...